CKD, however, is a complex disease and our animal model does not entirely reflect the clinical setting present in patients with CKD in terms of co-morbidities such as diabetes or obesity as well as possible interference with additional medication besides PPARγ agonists. Here, PPARG is linked to obesity disorder.